Rosetta Omics

Our CEO Wahid Awad, Ph.D. MBA Presenting Rosetta Omics to investors and potential partners on December 11th in Bruges, Belgium, during the HealthTech Investor Summit ! #Bruges #HTIS24 #RosettaOmics #HealthTech

📢 Exciting Announcement from Rosetta Omics 📢 We are honored to welcome Dr. Antoine Hollebecque, M.D., to our Scientific Advisory Board! Dr. Hollebecque is a senior medical oncologist at the world-renowned Gustave Roussy Cancer Center in Paris and a leading expert in drug development and precision medicine. With over 15 years of experience in oncology, his contributions to the field are unparalleled. 🔬 Career Highlights: * Principal investigator for 50+ Phase I/II/III clinical trials and a contributing investigator in 400+ trials in the past decade. * Extensive research in biliary and pancreatic carcinomas, FGFR inhibitors, and cell-free DNA during his post-doctoral fellowship at Cancer Research UK Manchester Institute * Published 230+ peer-reviewed articles in leading journals, including @New England Journal of Medicine, Nature Medicine, and Cancer Discovery. 🌟 Global Recognitions: Dr. Antoine Hollebecque is an active member of ESMO - European Society for Medical Oncology, American Society of Clinical Oncology (ASCO), and the French Federation of Gastrointestinal Oncology (FFCD), and his work continues to shape the future of oncology research. As we embark on our mission to revolutionize precision oncology through multiomics and AI, Dr. Hollebecque’s expertise will be invaluable in accelerating innovation and patient impact. Welcome aboard, Dr. Hollebecque! Together, we will transform cancer care. #RosettaOmics #Oncology #PrecisionMedicine #DrugDevelopment #ScientificAdvisoryBoard Association Jeunes Chercheurs de Gustave Roussy Gustave Roussy Transfert Paris Saclay Cancer Cluster (PSCC) Medicen Paris Region France Biotech HealthTech For Care Agoranov Bpifrance

If you missed it, here is the webinar of our CEO Wahid Awad, Ph.D. MBA speaking about precision medicine in cancer and Rosetta’s vision : https://lnkd.in/ekS6Wgac

Join us today at 11 AM EST for a webinar with Rosetta Omics "Introducing Rosetta Omics: Using Multi-Omics & AI to Enhance Precision Medicine in Oncology" Click below to register for free. #multiomics #precisionmedicine #ai #freewebinar https://lnkd.in/eqhjH94t

🚨 Rosetta News Alert! 🚨 We are excited to announce that our Founder & CEO Dr. Wahid Awad, Ph.D. MBA will be pitching Rosetta Omics to investors on December 11th in Bruges, Belgium, during the HealthTech Investor Summit! A big thank you to MEDVIA and the incredible team — Henk Joos, Rita Prota, Lindsay Nuytten — for organizing this amazing event, supported by 23 sponsors. Stay tuned for updates as we showcase how Rosetta Omics is revolutionizing precision medicine in oncology using spatial and multiomics data coupled with advanced AI algorithms to support physicians! #Bruges #HTIS24 #RosettaOmics #HealthTech Kevin Adam, PhD, MBE Medicen Paris Region Paris Saclay Cancer Cluster (PSCC) France Biotech HealthTech For Care Bpifrance Agoranov Blue Factory ESCP Hello Tomorrow Les Deeptech 🚀 CCI Paris Business France Choose Paris Region Région Ile de France CCI Paris IdF European Commission

Be ready to watch Our CEO Dr. Wahid Awad, Ph.D. MBA on 16 October. 20/15 Visioneers

🚀📢 Exciting Announcement! 📢🚀 We are very happy to announce that Rosetta Omics is expanding its strategic advisory board with esteemed international KOLs from the pharmacutical industry! Please join us to welcome Dr. Hugues RENAUT! About Hugues RENAUT, PhD/MBA After having worked several years in various hospitals, Hugues has spent 30+ years in the pharma industry (Servier), driving business successively in Europe, Canada, China, South-America, Africa and Middle East, while being at the same time part of a Global Deal Committee and representing his company at the EFPIA - European Federation of Pharmaceutical Industries and Associations as European Market Committee vice-chair and Patient Access Committee member. Hugues is now supporting healthcare innovations through business angel investment activities (LBAN - Luxembourg Business Angel Network & Angels Santé), advising funds, start-ups and CEOs through his company Health Care Advisory. « I am glad to support the future development of Rosetta Omics, a very promising start-up in precision medicine, by joining its Advisory Board », added. Dr. RENAUT. #AdvisoryBoard #PrecisionMedicine #KOLs #pharma #ClinicalTrials #ArtificialIntelligence #RosettaOmics #CancerResearch

🚀 Big News Alert! 🚀 We are very happy to announce that Rosetta Omics have been named one of Hello Tomorrow’s Deep Tech Pioneers! 🌍 The email reads : "Congratulations !! We’re excited to announce that your groundbreaking venture, Rosetta Omics, has been selected as one of the esteemed Hello Tomorrow Deep Tech Pioneers! This prestigious recognition marks a pivotal moment in your journey to transform the world through innovation. Out of 4,600 applications from 120 countries, your project distinguished itself as a leading light in deep tech. As a Deep Tech Pioneer, you’ll gain exclusive, year-round access to a wealth of opportunities within our dynamic community". ✨ Join us at the 10th Hello Tomorrow Global Summit on March 13-14, 2025, in Paris and connect with the world’s top innovators, industry leaders, investors, and deep tech visionaries. This summit is where groundbreaking ideas meet powerful networks—let's shape the future of deep tech together! Don’t miss out! 👉https://lnkd.in/g8keznYm

🌟 Rosetta Omics CEO Wahid Awad, Ph.D. MBA and CSO Kevin Adam, PhD, MBE have participated in the AI for Health summit 2024 at STATION F last week! 🚀 The event was a remarkable experience, made even more special by being invited to the exclusive investors tour, where we had the opportunity to network one-on-one with VCs actively investing in AI and healthcare innovation. This year’s summit, organized by Artifact and co-founded by Johnson & Johnson Innovative Medicine, brought together 2,000 participants—a true testament to the growing momentum in the field of AI & Health. Beyond the inspiring discussions, I was delighted to reconnect with old friends and forge new connections that will undoubtedly shape the future of healthcare. At Rosetta Omics, we’re at the forefront of transforming oncology through AI-powered precision medicine. By integrating advanced spatial and multiomics data, we’re uncovering novel biomarkers and validating therapeutic targets, enabling more effective and personalized cancer treatments. Our mission is to empower physicians with tools to deliver the right treatment to the right patient at the right time. Events like this remind me how innovation, collaboration, and shared vision can truly revolutionize healthcare. We look forward to being back next year and contributing even further to the science and innovation in this transformative era of healthcare and AI. #AIforHealth #PrecisionMedicine #Oncology #Biotech #Innovation #StationF #RosettaOmics

🌟 Exciting Announcement 🌟 We are very happy to welcome Anne De Landsheer to the Advisory Board of Rosetta Omics! 🎉 Anne brings a wealth of experience in Executive Search and Talent Management, with over 16 years in the Pharmaceutical industry and a decade of expertise in Life Sciences. As the founder of PEAK LIFECYCLES HR - Europe & the US, Anne has demonstrated exceptional leadership, guiding businesses in Talent Acquisition and the development of senior executives across the US and Europe. Her distinguished career includes: ✔️ Leading the Life Sciences Practice at Korn Ferry Executive Search. ✔️ Collaborating with early-stage and fast-growing organizations to build senior management teams. ✔️ Developing relationships with the Global Life Sciences community in Europe and the USA, including AESC, Jefferies, French-American Chamber of Commerce - New York, HTIDs by HealthTech For Care) and France Biotech. ✔️ Serving as a Board Member at REGEnLIFE, a cutting-edge Medtech company focused on brain-gut axis therapies. Anne’s academic background further reflects her expertise: 📚 Master’s in Neurosciences from the UMass Boston 📚 MBA from ESCP Business School 📚 MS Management from ESSEC Business School. At Rosetta Omics, we are committed to revolutionizing cancer precision medicine by integrating multiomics data, clinical insights, and AI-algorithms. Anne’s strategic vision and deep understanding of the Life Sciences ecosystem will be invaluable in driving our mission forward and building the best global teams to achive it. Please join us in welcoming Anne to the Rosetta Omics family as we continue to innovate and make strides in transforming cancer care. 🚀 #RosettaOmics #LifeSciences #PrecisionMedicine #AdvisoryBoard #Leadership